Health insurance company Clover Health (NASDAQ: CLOV) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 55.6% year on year to $743.2 million. The company’s full-year revenue guidance of $2.96 billion at the midpoint came in 1.7% above analysts’ estimates. Its GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

Is now the time to buy CLOV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Clover Health’s second quarter results were met with a positive market reaction, driven by strong Medicare Advantage membership growth and improved profitability. Management credited the quarter’s performance to the expansion of its Clover Assistant AI platform and disciplined focus on core markets, particularly New Jersey and Georgia. CEO Andrew Toy emphasized that “better clinical care leads to stronger cohort economics,” pointing to the impact of maturing member cohorts under the company’s technology-driven care model. The company also cited favorable medical cost trends and improvements in operating leverage as contributing factors.

Looking ahead, Clover Health’s updated guidance is shaped by continued maturation of its member cohorts and flexibility provided by its higher CMS star rating for payment year 2027. Management believes that as more members engage with the Clover Assistant platform over time, clinical and financial outcomes will continue to improve. CEO Andrew Toy stated, “The higher star rating gives us more room to reinvest in members, maintain a highly competitive product, support growth, and expand profitability.” The company is also preparing for ongoing investments in both its flagship technology and operational capabilities, with the goal of sustaining growth and delivering improved profitability in future periods.

Key Insights from Management’s Remarks

Clover Health’s management pointed to technology adoption, cohort maturation, and disciplined market focus as critical to the quarter’s financial performance and improved outlook.

• Clover Assistant expansion: The company’s AI-powered Clover Assistant platform continues to see increased uptake among physicians, supporting more accurate and timely care decisions. Management highlighted that over two-thirds of the total membership is managed with the platform, with engagement improving as member tenure increases.
• Cohort maturation impact: As members remain longer with Clover Health, their engagement with care management tools leads to improved economics. Management explained that new member cohorts typically show a $70 increase in gross profit per member per month (PMPM) as they transition from year one to year two, illustrating the compounding effect of longer-term relationships.
• Core market concentration: Membership growth remains concentrated in New Jersey and Georgia, where Clover Health believes it has the strongest ability to clinically engage members and manage long-term unit economics. This focus is intended to maximize the impact of the care model and avoid expansion for the sake of top-line growth.
• Medical trend management: The quarter benefited from favorable inpatient utilization trends and improvements in dental and Part D (prescription drug) cost management, areas targeted for operational enhancement. Management noted that outpatient trends, while elevated, remain within expectations.
• Operating leverage and investment discipline: The company achieved operating margin improvement through scaling its business and maintaining expense discipline, while also investing in enhancements to the Clover Assistant platform and operational infrastructure such as claims processing automation.

Drivers of Future Performance

Clover Health’s near-term and full-year outlook are anchored by the ongoing maturation of member cohorts and the operational flexibility enabled by its higher star rating.

• Cohort-driven profitability gains: Management expects continued improvements in profitability as a larger proportion of members transition into later stages of engagement with the Clover Assistant platform. These maturing cohorts are projected to deliver stronger gross profit and offset near-term pressure from newer members.
• Star rating flexibility: The recent recalculation of Clover Health’s star rating to four and a half stars for 2027 provides added flexibility to reinvest in member benefits, support competitive positioning, and balance growth with profitability. However, management cautioned that the underlying earnings trajectory is still primarily driven by cohort maturation, not the rating itself.
• Operational investments and risk management: The company is increasing investment in both its technology platform and administrative automation, aiming to enhance clinical quality and lower overhead costs. Management also identified ongoing market disruption and cost trend uncertainties as factors they are monitoring closely.

Catalysts in Upcoming Quarters

Moving forward, our analysts will be monitoring (1) the continued maturation and retention of member cohorts managed under Clover Assistant, (2) progress in scaling operational automation and back-office AI initiatives to drive margin improvement, and (3) changes in the competitive and regulatory landscape—including CMS decisions on star ratings and any further market disruptions. Results in these areas will be critical for sustaining momentum into 2027 and beyond.

Clover Health currently trades at $4.52, up from $4.19 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.